CBD and Autism
A recently published observational study on the effects of CBD-Enriched cannabis extract on Autism Spectrum Disorders highlights the need for double-blind placebo-controlled studies to evaluate the effectiveness of CBD on Autism.
The standardized extract in this study contained a proportion of ~75/1 CBD/THC and was administered orally in capsules containing 25 or 50 mg of CBD and ~0.34 or 0.68 mg of THC.
A titration process was used to gradually increase the dosage based on patient condition and response to therapy. the average initial dose of CBD was ~2.90 mg/kg/day and 4.55 mg/kg/day after titration.
17% out of the cohort suspended the treatment due to adverse effects, which may be related to concomitant therapy changes or potential drug interactions.
The following symptom categories were tracked:
1. Attention-Deficit/Hyperactivity Disorder (ADHD);
2. Behavioral Disorders (BD);
3. Motor Deficits (MD);
4. Autonomy Deficits (AD);
5. Communication and Social Interaction Deficits (CSID);
6. Cognitive Deficits (CD);
7. Sleep Disorders (SD);
8. Seizures (SZ).
At least 60% of patients presented improvements of 20% or more in ADHD, MD, CSID, BD, SD, and SZ.